Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06552260 · ClinicalTrials.gov registry record · Early Phase 1
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
A Early Phase 1 study of Glioblastoma and Brain Tumor, sponsored by Ugonma Chukwueke.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT06552260 is a Early Phase 1 study of Glioblastoma and Brain Tumor that is actively recruiting participants, run by Ugonma Chukwueke. The registered enrollment target is 27 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06552260, a Early Phase 1 study of Glioblastoma and Brain Tumor, is actively recruiting participants, sponsored by Ugonma Chukwueke.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Conditions Studied
Interventions
- DRUG Troriluzole
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2027-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06552260
The ClinicalTrials.gov registry entry for NCT06552260 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (75% lower). The listed sponsor is Ugonma Chukwueke, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Troriluzole is the first listed.
NCT06552260 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06552260 about?
NCT06552260 is a clinical study titled "A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma". This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
What is the current status of trial NCT06552260?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2025-02-19. Estimated completion is 2027-08-01.
What conditions does trial NCT06552260 study?
This clinical trial studies the following conditions: Glioblastoma, Brain Tumor, Recurrent Glioblastoma.
What interventions are being tested in trial NCT06552260?
The interventions under investigation include: Troriluzole (DRUG).
Who is sponsoring clinical trial NCT06552260?
This trial is sponsored by Ugonma Chukwueke, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06552260 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.